Vaxart (NASDAQ:VXRT) The company is working on a vaccine for the novel coronavirus that works via tablets instead of injection. If Vaxart reports positive results from this clinical trial, investors will likely see shares of VXRT stock soar higher. Be first to capitalize on, in my opinion the best alternative for Covid 19, a oral pill solution
And the clinical trial showed that it already works.
Hold this stock for a few months and it'll be worth 30x. At least.